Results 201 to 210 of about 510,697 (405)
ABSTRACT Psoriatic arthritis (PsA) is a chronic immune‐mediated disease with heterogeneous joint and skin manifestations. Although biologic therapies targeting TNFα, IL‐17, and IL‐23 have transformed PsA management, sex‐specific differences in efficacy and treatment persistence remain underexplored.
Keita Ohyachi +5 more
wiley +1 more source
Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis [PDF]
OBJECTIVES:\ud To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.\ud \ud METHODS:\ud Original studies reporting costs of RA or AS were searched systematically.
Ament, A.J.H.A. +4 more
core +2 more sources
Angiogenic and Inflammatory Properties of Psoriatic Arthritis [PDF]
Toshiyuki Yamamoto
openalex +1 more source
B-mode ultrasound in the uveitis in the psoriatic arthritis without skin lesion [PDF]
José Alex +3 more
openalex +1 more source
POS0227 SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS [PDF]
Signe Holm Nielsen +8 more
openalex +1 more source
ABSTRACT Generalized pustular psoriasis (GPP) is a heterogeneous, systemic neutrophilic inflammatory disease, characterized by chronic symptoms and recurrent flares, which can be potentially life‐threatening. Spesolimab, an interleukin‐36 receptor antagonist, has been approved to treat GPP flares in many countries including Japan.
Akimichi Morita +12 more
wiley +1 more source
44007 Risankizumab Long-Term Safety in Patients With Psoriatic Disease: Integrated Interval Analyses From Psoriasis and Psoriatic Arthritis Clinical Trials [PDF]
Kenneth B. Gordon +7 more
openalex +1 more source
CXCL4 is a novel inducer of human Th17 cells and correlates with IL‐17 and IL‐22 in psoriatic arthritis [PDF]
Alsya J. Affandi +7 more
openalex +1 more source
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara +7 more
wiley +1 more source

